Delivery Order SPE2DB20D2104-SPE2DB25FMYUN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 40 mg tablets (30-count units) on April 24, 2025. This competitively awarded, firm fixed price delivery order is scheduled for completion by May 15, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count units) on September 5, 2025, with an ultimate completion date of September 26, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. TAGRISSO is a targeted cancer therapy used in the treatment of non-small cell lung cancer, reflecting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,325.14 for TAGRISSO 80 mg tablets (30-count units) on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription oncology medication used primarily in the treatment of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $42,460.34 for TAGRISSO 80 mg tablets (30-count units) on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription pharmaceutical used in oncology treatment, reflecting the...
- The Defense Logistics Agency awarded a $31,892.74 delivery order to AmerisourceBergen Drug Corp for TAGRISSO (80 mg tablets, 30-count package) under a firm fixed-price contract type. The award was issued on September 17, 2025, with an ultimate completion date of October 8, 2025, and represents a competitively awarded non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order, leveraging its established...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- The Defense Logistics Agency awarded a $10,662.57 firm fixed price delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count packages) on August 11, 2025, with an ultimate completion date of September 2, 2025. This non-set-aside contract represents a competitive award for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the Defense Logistics Agency's Medical...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 24, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this delivery order represents one...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYUNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 80 mg tablets (30-count units) with a firm fixed price arrangement. This non-set-aside contract was competitively awarded on August 25, 2025, with an ultimate completion date of September 16, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. TAGRISSO is a prescription oncology medication used in the treatment of non-small cell lung cancer, reflecting the Defense Logistics Agency's continued procurement of specialized pharmaceutical products to support military and veteran healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support defense health programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to fulfill competitive federal procurement requirements across multiple therapeutic domains, from specialty oncology medications to vaccines and generic pharmaceuticals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 8/25/25 |